Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
Conditions:  Uveal Melanoma;  Metastatic Interventions:  Drug: 4.7 microCi 225Ac-MTI-201;  Drug: 9.5 microCi of 225Ac-MTI-201;  Drug: 19 microCi of 225Ac-MTI-201;  Drug: 38 microCi of 225Ac-MTI-201;  Drug: 76 microCi of 225Ac-MTI-201;  Drug: 152 microCi of 225Ac-MTI-201;  Drug: 254 microCi of 225Ac-MTI-201;  Dr ug: 424 microCi of 225Ac-MTI-201;  Drug: 564 microCi of 225Ac-MTI-201;  Drug: 750 microCi of 225Ac-MTI-201;  Drug: 998 microCi of 225Ac-MTI-201;  Drug: 1327 microCi of 225Ac-MTI-201 Sponsors:  Modulation Therapeutics, Inc.;  H. Lee Moffitt Cancer Center and Research Institute Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Eye Cancers | Melanoma | Research | Skin Cancer | Uveal Melanoma